Tags

Type your tag names separated by a space and hit enter

Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
Am J Cardiol. 2008 Apr 17; 101(8A):44B-47B.AJ

Abstract

Over the years, niacin has gained recognition as an atheroprotective agent, in part because of its capacity to lower the plasma levels of cholesterol, triglycerides, and very-low- and low-density lipoproteins and to substantially raise high-density lipoprotein. In high doses, niacin has also been reported to lower the plasma level of lipoprotein(a) (Lp[a]). However, the published research on the subject suffers from a lack of uniformity regarding patient selection, drug dose, length of administration, and methods for plasma Lp(a) quantification. In this report, the authors examine the most relevant niacin-related Lp(a) studies and hypothetical mechanisms of drug action, also considering the emerging notion of Lp(a) as a potential proinflammatory entity.

Authors+Show Affiliations

Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA. ascanu@medicine.bsd.uchicago.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

18375241

Citation

Scanu, Angelo M., and Ravi Bamba. "Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical Considerations." The American Journal of Cardiology, vol. 101, no. 8A, 2008, 44B-47B.
Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol. 2008;101(8A):44B-47B.
Scanu, A. M., & Bamba, R. (2008). Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. The American Journal of Cardiology, 101(8A), 44B-47B. https://doi.org/10.1016/j.amjcard.2008.02.031
Scanu AM, Bamba R. Niacin and Lipoprotein(a): Facts, Uncertainties, and Clinical Considerations. Am J Cardiol. 2008 Apr 17;101(8A):44B-47B. PubMed PMID: 18375241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. AU - Scanu,Angelo M, AU - Bamba,Ravi, PY - 2008/6/14/pubmed PY - 2008/7/3/medline PY - 2008/6/14/entrez SP - 44B EP - 47B JF - The American journal of cardiology JO - Am J Cardiol VL - 101 IS - 8A N2 - Over the years, niacin has gained recognition as an atheroprotective agent, in part because of its capacity to lower the plasma levels of cholesterol, triglycerides, and very-low- and low-density lipoproteins and to substantially raise high-density lipoprotein. In high doses, niacin has also been reported to lower the plasma level of lipoprotein(a) (Lp[a]). However, the published research on the subject suffers from a lack of uniformity regarding patient selection, drug dose, length of administration, and methods for plasma Lp(a) quantification. In this report, the authors examine the most relevant niacin-related Lp(a) studies and hypothetical mechanisms of drug action, also considering the emerging notion of Lp(a) as a potential proinflammatory entity. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/18375241/Niacin_and_lipoprotein_a_:_facts_uncertainties_and_clinical_considerations_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(08)00255-5 DB - PRIME DP - Unbound Medicine ER -